Meeting
2018 ASCO Annual Meeting
Association between Helicobacter pylori infection and outcome in advanced gastric cancer patients treated with S-1 adjuvant chemotherapy.
Authors
Satoshi Nishizuka
Iwate Medical University School of Medicine, Morioka, Japan
Satoshi Nishizuka , Gen Tamura , Masahiro Nakatochi , Takeshi Iwaya , Virginia A. Espina , Lance A. Liotta , Keisuke Koeda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4043)
DOI
10.1200/JCO.2018.36.15_suppl.4043
Abstract #
4043
Poster Bd #
232
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
First Author: Kohei Shitara
Poster
2023 ASCO Annual Meeting
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.
First Author: Yelena Y. Janjigian
Poster
2023 ASCO Annual Meeting
Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.
First Author: Jaume Capdevila
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Bintrafusp alfa plus paclitaxel for advanced gastric cancer as a second-line treatment: An open label, single-arm, phase Ib/II study.
First Author: Choong-kun Lee